Abstract
EFFICACITY AND TOLERABILITY OF ARTESUNATE AMODIAQUINE (ASAQ) VERSUS ARTHEMETHER LUMEFANTRINE (AL) IN THE TREATMENT OF UNCOMPLICATED PLASMODIUM FALCIPARUM MALARIA AMONG CHILDREN FROM 0 TO 60 MONTHS IN THREE PROVINCES IN CHAD

Issa Ramat Adam, Akono Ntonga Patrick, Nack Jacques, Abakar Idriss Lawane, Samafou Kemba and Hamit Mahamat Alio*

ABSTRACT

The Chadian government recommends three artemisinin-based combinations for the treatment of uncomplicated Plasmodium falciparum malaria: Artemether–Lumefantrine (AL), Artesunate–Amodiaquine (ASAQ). Due to the treatment of emerging anti-malarial drug resistance, it is important to periodically monitor the efficacy of artemisinin-based combination therapy (ACT). This study evaluated these medications therapeutic efficacy in Massakory, Mondo, and Dourbali Provinces. Enrollment occurred between January and April 2020. Study participants were children with P. falciparum monoinfection from each provincial capital. Participants received a 3-day course of a quality-assured artemisinin based combination and were monitored for 28 days (AL and ASAQ arms). We recruited 1130 children of whom 570 (ASAQ group) and 560 (AL group) were fully followed-up. The cure rates for ASAQ and AL treatments were 95.8% and 92.5% on day 28 respectively. Overall, both drugs were well tolerated at the clinical and biological level, no late parasitological failures have been recorded in AL and ASAQ groups. This study shows that ASAQ and AL are still effective and well tolerated. Accordingly, they can continue being used to treat uncomplicated malaria in Chad. However, monitoring of their efficacy should remain a priority for health authorities.

Keywords: Malaria, Efficacy, Plasmodium falciparum, Artesunate-Amodiaquine, Artemether-Lumefantrine.


[Full Text Article]

Login





Forgot Password  |  Register

Indexing

Best Paper Awards

European Journal of Biomedical and Pharmaceutical Sciences (EJBPS) will give best paper award in every issue in the form of money along with certificate to promote research activity of scholar.

Best Article of current issue :

Dr. Dhrubo Jyoti Sen

Download Article : Click here

News & Updation

  • EJBPS: JANUARY ISSUE PUBLISHED

    JANUARY 2022 Issue has been successfully launched on 1 January 2022.

  • EJBPS New Impact Factor

    Its our Pleasure to Inform you that EJBPS Impact Factor has been increased from 5.467 to 6.044, due to high quality Publication at International Level.

  • Index Copernicus Value

    EJBPS Received Index Copernicus Value 77.3, due to High Quality Publication in EJBPS at International Level

  • Journal web site support Internet Explorer, Google Chrome, Mozilla Firefox, Opera, Saffari for easy download of article without any trouble.

    .

  • Article Invited for Publication

    Dear Researcher, Article Invited for Publication  in EJBPS coming Issue.

     

UG/PG/Ph.D Research Publication

Research Scholar of UG/PG/Ph.D can Submit their Research Article/Review Article/Case Study/Short Communication for Publication in EJBPS

Downloads

Copyright From

Covering Letter

                        Author Instruction 
 

PLAGERLUM REPORT